INHERITED DYSLIPIDAEMIC DISORDERS CONTRIBUTING TO CORONARY HEART DISEASE
AbstractBackground: Lipoprotein (a) [Lp (a)] is an established independent risk factor for prematuremyocardial infarction (MI)/coronary artery disease (CAD). The study was conducted to determine thevalue of Lp (a) in prediction of CAD or MI in the offspring at risk. Methods: A total of 160 subjectswere investigated. Serum Lp (a) was measured by ELISA, serum total cholesterol, triglycerides (TG)and HDL-Cholesterol by enzymatic colorimetric methods using standard kits. Results: Differences inlevels of total Lp (a) and cholesterol were observed between patients and controls. Both Lp (a)(16.23±1.95 mg/dL) and cholesterol (175.00±7.60 mg/dL) of group A (patients) were higher than thecorresponding controls. However an opposite trend in results was noted for serum HDL-Cholesterol inpatients vs. controls. Conclusion: Persons found to have elevated levels of Lp (a) should focus oncontrolling the known modifiable risk factor for heart disease, especially smoking,hypercholesterolemia, obesity, hypertension and sedentary life style.Keywords: Dyslipidaemia, Coronary Artery Disease, CAD, Lipoprotein (a), MyocardialInfarction, MI, Cholesterol, HDL-Cholesterol, LDL-Cholesterol, Triglycerides
Rallidis LS, Papageorgakis NJ, Maglou AA, Exadactylos NJ,
Tsitouris GK, Papasteriadis EG. High incidence of
dyslipdaemia in the offspring of Greek man with premature
coronary artery disease. Eur Heart J 1998;19:395–401.
Robert S. Inherited disorder contributing to coronary heart
disease. Disease Inst 1996;2:876–83.
Backer GD, Henauw SD, Sans S, Nicaud V, Masana L,
Visvikis S. A comparison of lifestyle, genetic, bioclinical and
biochemical variables of offspring with and without family
histories of premature coronary heart disease: The experience
of the European Atherosclerosis Research Studies. J
Cardiovascular Risk 1999;6:183–8.
Genest Jr JJ, Martin-Muleny SS, McNamara JR, Ordovas
JM, Jennefer J, Mayres RH. Familial lipoprotein disorder in
patients with premature coronary artery disease. Circulation
Srinavasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson
GS. Racial (black–white) differences in serum lipoprotein (a)
distribution and its relation to parental myocardial infraction in
children: Bogalusa Heart Study. Circulation 1991;84:160–167.
Balleul S, Couderc R, Rossignol C, Fermannian J, Boutouchent
F, Farnier, M. Lipoprtein (a) in childhood: Relation with other
atherosclerotic risk factors and family history of
atherosclerosis. Clin Chem 1995;41:241–5.
Ahmad S, Yaqoob Z, Samad A. Acute myocardial infarction
in an eighteen years old Pakistani girl without classical risk
factors for premature coronary artery disease (case report and
review of the literature). PJC 1997;11:1271–80.
Kannel WB, McGee D, Gordon J. A general cardiovascular
risk factor profiles. The Framingham Study. Am J Cardiol
J Ayub Med Coll Abbottabad 2008;20(4)
Gensini GF, Comeglio M, Collella A. Classical risk factors
and emerging elements in the risk profile for coronary artery
disease. Eur Heart J 1998;19(Suppl A):A53–A61.
Berg K. A new system in man: The Lp (a) system. Acta
Pathol Microbial Scand 1963;59:369–82.
Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Guar
VP. Effect of number of Apolipoprotein (a) Kingle 4
domains on immunochemical measurement of lipoprotein (a).
Clin Chem 1995;41(2):2246–55.
Igarashi Y, Yamura M, Ito M, Inuzuka H, Ojima K, Aziwa
Y. Elevated serum lipoprotein (a) is a risk factor for left
arterial thrombus in patients with chronic arterial fibrillation:
A Tran–esophageal Echocardiographic study. Am Hear J
Gaubatz JW, Hoogeveen RC, Hoffman AS. Isolation,
quantitation and characterization of stable complex formed
by Lp (a) binding to triglyceride–rich lipoproteins. J Lipid
Lippi G, Bassi A, Broco G. Lipoprotein (a) concentration is
not associated with venous thrombo-embolism in case control
study. Haemotologica 1999;84:726–9.
Bostom AG, Shemin D, Verhoef P. Prospective study of
coronary heart disease incidence in relation to fasting total
homocysteine, related genetic polymorphisms, and B–
vitamins: The Atherosclerosis Risk In Communities (ARIC)
Study. Circulation 1998;96:201–7.
Kim H, Marcovina SM, Edwards KL. Lipoprotein (a) as a
risk factor for maternal cardiovascular disease mortality in
Kindreds with familial combined hyperlipidemia or familial
hypertriglyceridaemia. Clin Genet 2001;60(3):188–97.
Friedwald WT, Levy RI, Fredhrickson DS. Estimation of
concentration of low-density lipoprotein cholesterol in
plasma without use of preparative ultracentrifuge. Clin Chem
Ahmad MS, Ahmad I. Effect of CAD duration of plasma
lipids and lipoproteins concentration. PJI 1995;5:83–6.
Assmann G, Schulte H. Relation of high–density lipoproteins
and triglycerides to incidence of atherosclerotic coronary
artery disease. (The PROCAM Experience). Am J Cardiol
Wood D. European and American recommendations for Coronary
Heart Disease. Eur Heart J 1998;19(Suppl A):A12–A19.
Robins SJ. Management of Lipid Disorders: A basis and
guide for therapeutic intervention. 1st Ed. Baltimore,
Williams and Wilkins, 1997;42:52–3.
Wong MS, Chew WLS, Aw TC. Serum Lipoprotein (a)
profile in Singaporean population. Patho 1997;31:225–9.
Angles C. Structural basis for the Pathophysiology of
Lipoprotein (a) in the atherothrombotic process. Braz J Med
Bio Res 1997;11:1271–80.
Rossl A, Baldo–Enzi G, Ganzaroli C, Coscetti G.
Relationship of early Carotid Artery disease with Lipoprotein
(a), Apolipoprotein B, and Fibrinogen in asymptomatic
essential hypertensive patients and normotensive subjects. J
Investig Med 2001;49(6):505–13.
Craig WY, Nevenux LM, Palomaki GF, Cleveland MM,
Haddo JE. Lipoprotein (a) as a risk factor for ischemic heart
disease: Meta–analysis of prospective studies. Clin Chem
Hegele RA, Freeman MR, Langer A, Connelly PW,
Amstrong PW. Acure reduction of Lipoprotein (a) by tissue–
type plasminogen activator. Circ 1992;85:2034–8.
Vella JC, Jover Vega GL, Denke MA, Grundy SM.
Metabolic basis of primary relation of lipoprotein (a) in 11–
years old adolescents to parental cardiovascular heart
disease. Clin Chem 1993;39(3):477–80.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.